BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24574752)

  • 1. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
    Baiz D; Dapas B; Farra R; Scaggiante B; Pozzato G; Zanconati F; Fiotti N; Consoloni L; Chiaretti S; Grassi G
    World J Gastroenterol; 2014 Jan; 20(3):795-803. PubMed ID: 24574752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
    Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
    Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising roles of mammalian E2Fs in hepatocellular carcinoma.
    Zhan L; Huang C; Meng XM; Song Y; Wu XQ; Miu CG; Zhan XS; Li J
    Cell Signal; 2014 May; 26(5):1075-81. PubMed ID: 24440307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
    Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells.
    Farra R; Dapas B; Pozzato G; Scaggiante B; Agostini F; Zennaro C; Grassi M; Rosso N; Giansante C; Fiotti N; Grassi G
    Dig Liver Dis; 2011 Dec; 43(12):1006-14. PubMed ID: 21831731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
    Huang IT; Dhungel B; Shrestha R; Bridle KR; Crawford DHG; Jayachandran A; Steel JC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):7-18. PubMed ID: 30474444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
    Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
    Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors.
    Shen Q; Uray IP; Li Y; Krisko TI; Strecker TE; Kim HT; Brown PH
    Oncogene; 2008 Jan; 27(3):366-77. PubMed ID: 17637753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.
    Shi K; Ru Q; Zhang C; Huang J
    Med Sci Monit; 2018 Mar; 24():1642-1653. PubMed ID: 29557391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Hui B; Shi YH; Ding ZB; Zhou J; Gu CY; Peng YF; Yang H; Liu WR; Shi GM; Fan J
    Cancer; 2012 Nov; 118(22):5560-71. PubMed ID: 22517429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.